Research on malaria and the fight against it. Covers red-blood-cell inflammation, malaria resurgence, drug-resistant parasites, and mosquito-based control.
A new review highlights the complex factors influencing mosquito-borne disease transmission, including climate change, mosquito control, and socioeconomic factors. Experts emphasize the need for a coordinated approach to address the spread of diseases like malaria and dengue.
Researchers at the University of São Paulo found that anti-cancer molecules effective against malaria parasites, eliminating them at both the asexual and gametocyte stages of development. This discovery paves the way for the development of new effective drugs.
Researchers have discovered a new vulnerability in the malaria parasite Plasmodium vivax, which can be targeted by antibodies to block liver infection and prevent relapses. The discovery provides a new target for developing a vaccine against P. vivax, the most widespread malaria parasite outside sub-Saharan Africa.
Researchers uncover molecular mechanism by which Plasmodium falciparum increases gametocyte production in response to stress, enabling rapid transmission to mosquitoes. The study identifies key regulators, including GDV1 and AP2-HS, that trigger a regulatory feedback loop to control gametocyte production.
Researchers at Lund University have identified a mechanism by which heme, released from damaged red blood cells, activates an inflammatory response. The kallikrein-kinin system pathway was found to be involved, leading to increased permeability and fluid leakage in surrounding tissues.
A recent study by the Ethiopian Public Health Institute and the JAMA Network has identified emerging drug and diagnostic resistance variants as contributing factors to Ethiopia's malaria resurgence. The study highlights the need for continued monitoring and adaptation of treatment strategies to combat the growing malaria epidemic.
A team of researchers at Brown University identified new genetic mutations in malaria parasites that make them less susceptible to current treatments. The findings, published in Nature Medicine, highlight the rapid spread of these variants and the need for improved surveillance and new therapies.
Researchers developed a new vaccination strategy that pairs mosquito-delivered parasites with antimalarial compounds, generating strong and durable immunity against malaria. The approach protected mice for up to two years, offering a potential 'vaccinate and boost naturally' method for prevention.
Researchers at the Batista Lab have identified a gap in current malaria vaccines, which only target one region of the parasite. Adding short peptides to these regions can broaden the immune response and improve protection.
A study by the University of Bonn and the Doherty Institute found that malaria infection permanently damages resident CD163 macrophages in the spleen, impairing their ability to recycle iron and communicate with other cells. This damage can lead to increased severity of future infections and worsened prognosis.
Researchers at UC Riverside are developing new treatments for malaria and babesiosis using naturally occurring compounds, including leelamine-derived isonitriles and pyrroloiminoquinones. The goal is to create oral treatments that can interrupt transmission of the parasites.
A new study finds that climate change has slightly increased malaria overall, but rising temperatures could increase risk in southern and East Africa while reducing it in warm regions like West Africa.
Researchers have created an affordable and highly effective mosquito repellent distilled from locally grown catnip plants, comparable to DEET-based products. The nepetalactone-based lotion has been shown to repel mosquitoes responsible for malaria transmission in Sub-Saharan Africa.
The article explores AI-driven transformations in digital health, including a novel malaria intelligence platform and the Centers for Medicare & Medicaid Services' Landmark ACCESS program. Genuine institutional change is crucial for safe clinical AI adoption.
A study published in Frontiers in Cellular and Infection Microbiology found that healthy infant gut microbiomes are linked to reduced risk of malaria. Babies with beneficial microbes like Bifidobacterium were less likely to develop the disease. However, further research is needed to confirm this association.
Researchers at the German Center for Infection Research have developed a promising single-dose malaria treatment called SPAP, which targets the malaria parasite through multiple mechanisms. The four-drug combination therapy has shown significant promise in improving malaria treatment and could be a major advancement in sub-Saharan Africa.
Researchers at Johns Hopkins Bloomberg School of Public Health discovered that a common yeast called Rhodotorula taiwanensis can lure and trap the Anopheles gambiae mosquito, the principal malaria-transmitting mosquito in Africa. The yeast's blend of scent chemicals attracts mosquitoes via their sense of smell, primarily through odoran...
A global study confirms mosquito nets reduce malaria cases by up to 68%, but highlights regional variations and the need for locally adapted control strategies. The researchers warn that relying on ITNs alone may not be enough, especially in areas with established insecticide resistance.
A new malaria vaccine has demonstrated strong protection against the disease, inhibiting transmission by mosquitoes and requiring no refrigeration. The vaccine targets two critical stages of the malaria parasite's life cycle, reducing infection rates by up to 80%.
A PSU-led research team has developed a novel chemical compound, T111, that shows promise for treating and preventing malaria. The compound targets all three major life-cycle stages of the malaria parasite, making it a strong candidate for a single-encounter radical cure.
A study by Children's Hospital of Philadelphia researchers found that over one in four pediatric patients treated for malaria in the US had a delay in diagnosis, leading to more severe infection and longer hospital stays. The study emphasized the need for prompt diagnosis and prevention of imported cases to improve patient outcomes.
Researchers have identified PEG400 as a potential antimalarial therapy by targeting the malaria parasite's enzyme Falcipain-2. This study offers hope for selective and cumulative benefits in reducing malaria treatment challenges.
The malaria parasite uses its own messenger RNA to disrupt the host's immune system, causing chaos and evading detection. By inserting its mRNA into monocyte nuclei, the parasite jams internal communications, shutting down immune protein production and triggering an immune response that fails to detect the parasites.
Researchers discovered that malaria parasite PI3K suppresses 'eat-me' signal to evade host immune system. By inhibiting PI3K, phosphatidylserine exposure increases, enhancing macrophage recognition and clearance of infected red blood cells.
Researchers have developed a new microscopy method that uses polarized light and a magnetic field to detect malaria parasites in blood. The method provides quantitative information and can be used for faster and more objective detection of malaria.
Children who survive severe childhood malaria experience cognitive and academic impairment that persists into adolescence. The correlation highlights the urgent need for better prevention strategies and therapies to minimize lasting effects of the disease.
A team from The University of Osaka has identified the MIC11 gene as essential for parasite egress, disrupting the parasite life cycle. This finding could guide the development of novel treatments for parasite-borne diseases.
A new study by Harvard T.H. Chan School of Public Health found that Anopheles darlingi mosquitoes are evolving to evade insecticides, threatening malaria control efforts in South America. The study sequenced complete genomes of over 1,000 mosquitoes across six countries and identified resistance-related genes.
Rice bioengineer Omid Veiseh has been awarded a $2.2 million grant to develop implantable cell factory platforms that can deliver therapeutic antibodies over extended periods. The platform aims to reduce dosing frequency and improve access to biologic therapies in low- and middle-income countries.
Researchers have identified a unique protein named Aurora-related kinase 1 (ARK1) essential for the malaria parasite's survival and transmission. Turning off ARK1 in the lab causes replication to fail, preventing disease progression and transmission.
The collaboration aims to accelerate the discovery and development of next-generation antimalarial drugs, with a focus on global access and affordability. Calibr-Skaggs and Kainomyx will jointly advance promising hits through the drug discovery pipeline, with a shared commitment to open publication.
A study published in PNAS reveals that Sudanese Copts have acquired a genetic variant that protects them from contracting malaria after mixing with other Sudanese populations. The acquisition of this variant took place over 1,500 years and has led to an evolutionary adaptation to the disease.
Researchers discovered a previously unknown stage, nicknamed the 'Crown' stage, crucial for malaria parasite reproduction. This stage helps ensure proper internal structure passage to daughter cells.
Researchers develop a synthetic compound that acts on all three stages of the disease cycle, eliminating parasites from human blood and liver, and preventing transmission to mosquitoes. The molecule has shown effectiveness against P. vivax and P. falciparum species.
A new rapid test using a mobile phone has been developed to identify the most severe cases of imported malaria within minutes. The test uses video analysis and two biomarkers to predict which patients are at risk of developing severe disease.
Researchers found that methylene blue can reverse brain damage caused by cerebral malaria and identified a nine-gene blood signature to diagnose the disease. The study's findings offer new clues on immune processes involved in brain injury and suggest potential for early intervention and clearer treatment decisions.
Public Health Alerts provide concise, data-driven information on disease outbreaks and urgent health events. The new series, launched by NEJM Evidence and CIDRAP, offers expert-reviewed reports to support public health evidence-based care.
Researchers have developed a new antimalarial drug candidate, MK-7602, which targets the malaria parasite at multiple stages of its life cycle. The compound has shown potent activity against both Plasmodium falciparum and Plasmodium vivax, two common malaria parasites affecting humans.
A new study from the University of Copenhagen predicts that climate change could create more favorable conditions for malaria mosquitoes, exposing millions to increased risk of infection. The researchers warn that if left unchecked, this could put between 200 million and up to 1 billion people at additional risk.
Malaria messaging has been shown to increase the use of insecticide-treated nets, particularly among women in Uganda. The study used propensity score matching to isolate the effect of messaging, finding a 5.1% increase in net use among exposed women and a 4.3% increase among caregivers of children.
Researchers from Heidelberg University discovered that malaria parasites use right-handed helices to navigate through tissues, a key finding with implications for improving drug and vaccine testing. The parasite's asymmetrical body plan enables it to control its motion and transition between compartments more efficiently.
A clinical trial in Africa has discovered a single-dose treatment combining sulfadoxine, pyrimethamine, artesunate, and pyronaridine (SPAP) that is as effective as traditional multi-day treatments in curing uncomplicated malaria. The study addresses the growing threat of drug-resistant malaria parasites and improves treatment adherence.
Researchers have created a model that can handle complex mosquito behavior and its impact on human diseases. The study reveals surprising findings, such as it may be better to let a mosquito bite you in terms of overall transmission.
Researchers find that malaria parasites use a chemical reaction powered by hydrogen peroxide decomposition to make their iron crystals spin. This motion may be crucial for the parasite's survival, helping it to eliminate excess toxic chemicals and efficiently store essential heme.
Researchers from the University of South Florida have used artificial intelligence and citizen science to identify what may be the first specimen of Anopheles stephensi — an invasive and deadly malaria-carrying mosquito — ever detected in Madagascar. The study demonstrates how AI-powered image recognition and public participation can t...
Research in the Amazon reveals that regions with intermediate forest degradation are more prone to malaria transmission due to increased contact between mosquitoes and humans. The study emphasizes the need for targeted interventions integrating vector control with forest conservation.
Researchers engineered a new strain of Metarhizium fungus that mimics flower scents to attract and kill mosquitoes. The floral-scented fungus is harmless to humans and breaks down naturally, making it a promising alternative to chemical pesticides.
A 30-year study in southern Sweden finds that rising spring temperatures have doubled the incidence of avian malaria, with a specific period from May 9 to June 24 being particularly critical. The researchers believe that warmer years trigger blood-sucking insects to seek out nests, allowing parasites to thrive and spread disease.
Researchers at Helmholtz Centre for Infection Research have identified a new drug candidate, Substance 31, that prevents the production of new proteins in malaria parasites. This approach has the potential to break through existing resistances and develop new therapeutic strategies against malaria infections.
Researchers at Columbia University Irving Medical Center have discovered new vulnerabilities in the malaria parasite's PfATP4 sodium pump, which could lead to more effective treatments. The study also identified a previously unknown binding partner essential for parasite survival.
A new monoclonal antibody has shown dose-dependent full protection against the malaria parasite with minimal side effects. Researchers found that a single injection of the antibody could provide months-long protection, offering a fundamentally different way to prevent infection before it starts.
A £2 million Wellcome Discovery Award will fund a five-year project to study the molecular interaction between Plasmodium falciparum and the placenta. The research aims to catalogue disrupted molecular and cellular pathways that could be targeted for intervention, contributing to the development of diagnostics and vaccines.
Researchers have unraveled the structure of two key malaria parasite proteins, offering opportunities for new vaccines that block mosquito transmission. The discovery is a significant step towards eradicating the deadly disease.
Researchers sequenced hundreds of Anopheles funestus mosquitoes to explore genetic variation and adaptation to control methods. The study provides new insights into the evolutionary patterns of this important human malaria-transmitting species.
Stefan Kappe, a leading expert in genetic engineering of parasites, has been appointed as the new Director of the Center for Vaccine Development and Global Health at UM School of Medicine. He will focus on developing genetically engineered live-attenuated pathogens to combat malaria infection.
A new class of insecticide, called spatial emanators, provides protection for up to a year against mosquitoes that spread malaria, as well as dengue, West Nile, yellow fever, and Zika. The breakthrough offers lasting protection in areas where malaria is prevalent and can be used day and night without heating or electricity.
Researchers developed a new method to identify functional plasma antibodies against malaria using mass spectrometry sequencing, providing valuable insight into protective antibody responses. The study identified a broadly neutralizing antibody with broad inhibitory activity against diverse PfEMP1 variants.
Researchers have found a way to rearrange atoms in a new generation of malaria drugs to make them more soluble, maintaining their effectiveness against drug-resistant parasites. This breakthrough could lead to an effective successor to artemisinin-based combination therapy.
The R21/Matrix-M malaria vaccine generates nearly identical antibodies to those following a natural infection, providing strong protection against the earliest life stage of malaria parasites. This long-lasting immunity is effective without requiring further adaptation.
A new network aims to improve malaria prevention among school-aged children in sub-Saharan Africa by uniting researchers, policymakers, and healthcare practitioners. The initiative will help fill knowledge gaps and develop guidance to support countries in addressing the burden of malaria in this age group.